Search results for "VLPs"

Article Virus-like Particles as Therapeutic Moieties of the Future
Rathore Virus-like particles (VLPs) are viral capsid shells assembled without encapsulated nucleic acid. These particles resemble native virions, are highly ordered and repetitive, and are approxi…

Article Removal of DNA and baculovirus from influenza virus-like particles using Capto™ Q
The chromatographic step uses Capto Q medium in flowthrough mode so that the VLPs pass through the column while the contaminants are retained; a method that allows higher stability of the product. Usi…

Article Addressing the Challenges in Downstream Processing Today and Tomorrow
Similar to viral vectors, VLPs present unique challenges because of their large size (2.5 x106 kDa). Q (14 kDa) is the most commonly used VLP. It is derived from the structural coat protein of this vi…

Article Ensuring Viral Safety of Viral Vaccines and Vectors
Sf9 cells are a common substrate for biological products such as VLPs. These contamination events highlight the limitations of current technologies; more vigilance is needed. Consequences of va…

Article Generating a Fully Processed Antibody
Many VLPs, for example, require two or more proteins to be produced in the right proportion to get the correct viral structure to mimic the virus itself. In the case of a protein needing cleavage …

Article Novel Vaccine Technologies Meet the Need for Pandemic and Therapeutic Solutions
Two different types of immunogenic particles are used: virus-like particles (VLPs) and recombinant protein micelles. Novavax’ seasonal and pandemic influenza vaccines consist of VLPs or recombinant pa…

Article The use of Capto™ Core 700 and Capto Q ImpRes in the purification of human papilloma virus like particles
Modified L1 protein was expressed in insect Sf9 cells using baculovirus vector, and allowed to spontaneously assemble into virus like particles (VLPs). A modern, scalable approach, based on two chroma…